# HLA Class-II Associated HIV Polymorphisms Predict Escape from CD4+ T Cell Responses

**Authors:** Nathan Erdmann, Victor Y. Du, Jonathan Carlson, Malinda Schaefer, Alexander Jureka, Sarah Sterrett, Ling Yue, Dario Dilernia, Shabir Lakhi, Jianming Tang, John Sidney, Jill Gilmour, Susan Allen, Eric Hunter, Sonya Heath, Anju Bansal, Paul A. Goepfert

PMC · DOI: 10.1371/journal.ppat.1005111 · PLoS Pathogens · 2015-08-24

## TL;DR

This study shows that CD4+ T cells can drive HIV evolution by selecting for viral escape mutations, which could inform future vaccine strategies.

## Contribution

The study introduces a novel computational method to identify CD4+ T cell-driven HIV escape mutations using HLA-II associated polymorphisms.

## Key findings

- 29 HLA-II associated HIV sequence polymorphisms were identified as potential CD4+ T cell escape mutations.
- CD4+ T cell responses to escape epitopes were significantly lower compared to non-escape epitopes.
- Longitudinal data confirmed that CD4+ T cells drive viral escape mutations following acute HIV infection.

## Abstract

Antiretroviral therapy, antibody and CD8+ T cell-mediated responses targeting human immunodeficiency virus-1 (HIV-1) exert selection pressure on the virus necessitating escape; however, the ability of CD4+ T cells to exert selective pressure remains unclear. Using a computational approach on HIV gag/pol/nef sequences and HLA-II allelic data, we identified 29 HLA-II associated HIV sequence polymorphisms or adaptations (HLA-AP) in an African cohort of chronically HIV-infected individuals. Epitopes encompassing the predicted adaptation (AE) or its non-adapted (NAE) version were evaluated for immunogenicity. Using a CD8-depleted IFN-γ ELISpot assay, we determined that the magnitude of CD4+ T cell responses to the predicted epitopes in controllers was higher compared to non-controllers (p<0.0001). However, regardless of the group, the magnitude of responses to AE was lower as compared to NAE (p<0.0001). CD4+ T cell responses in patients with acute HIV infection (AHI) demonstrated poor immunogenicity towards AE as compared to NAE encoded by their transmitted founder virus. Longitudinal data in AHI off antiretroviral therapy demonstrated sequence changes that were biologically confirmed to represent CD4+ escape mutations. These data demonstrate an innovative application of HLA-associated polymorphisms to identify biologically relevant CD4+ epitopes and suggests CD4+ T cells are active participants in driving HIV evolution.

In HIV, CD4+ T cells are best known as the primary targets of infection. Although emerging data has suggested a more active role in viral pathogenesis, the CD4+ T cell population remains relatively understudied. Using a novel computational approach, we predicted 29 different epitopes with mutations that potentially represent escape from CD4+ T cell responses. The predicted escaped epitopes were found to be less immunogenic than the wild type forms, suggesting that the identified escapes allow HIV to reduce its visibility to the immune system. Using longitudinal samples, we were able to show CD4+ T cells driving viral escape following acute infection. Overall, these findings significantly expand our knowledge of how CD4+ T cells can exert HIV control and influence HIV evolution, providing important implications to future vaccine development strategies.

## Linked entities

- **Proteins:** CD4 (CD4 molecule), CD8A (CD8 subunit alpha), IFNG (interferon gamma)

## Full-text entities

- **Genes:** HLA-DRB1 (major histocompatibility complex, class II, DR beta 1) [NCBI Gene 3123] {aka DRB1, HLA-DR1B, HLA-DRB, SS1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, LAMP1 (lysosome associated membrane protein 1) [NCBI Gene 3916] {aka CD107a, LAMPA, LGP120}, Nef [NCBI Gene 156110], Il2 (interleukin 2) [NCBI Gene 16183] {aka Il-2}, IL2 (interleukin 2) [NCBI Gene 403989], Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, CD4 (CD4 molecule) [NCBI Gene 713807], Mela (melanoma antigen) [NCBI Gene 17276] {aka 80kDa, Ag, env, gag, gag-pol, pol}, gag-pol (Gag-Pol) [NCBI Gene 155348], Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, GZMA (granzyme A) [NCBI Gene 3001] {aka CTLA3, HFSP}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, gag (Pr55(Gag)) [NCBI Gene 155030], HLA-DQB1 (major histocompatibility complex, class II, DQ beta 1) [NCBI Gene 3119] {aka CELIAC1, HLA-DQB, IDDM1}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, CD4 (CD4 molecule) [NCBI Gene 403931], TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Dr1 (down-regulator of transcription 1) [NCBI Gene 13486] {aka 1700121L09Rik, Dr1l, NC2, NC2beta}, IFNG (interferon gamma) [NCBI Gene 403801] {aka IFN-G, IFN-gamma}, Il7 (interleukin 7) [NCBI Gene 16196] {aka A630026I06Rik, Il-7, hlb368}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, IL7 (interleukin 7) [NCBI Gene 751768], ITGA4 (integrin subunit alpha 4) [NCBI Gene 3676] {aka CD49D, IA4}
- **Diseases:** acute infection (MESH:D000208), -3 (MESH:C537153), infected (MESH:D007239), AIDS (MESH:D000163), chronic infection (MESH:D000088562), AHI (MESH:D015658), AE (MESH:D018489), AH-5 (MESH:D007039)
- **Chemicals:** DTT (MESH:D004229), brefeldin A (MESH:D020126), CO2 (MESH:D002245), 7-AAD (MESH:C025942), Monensin (MESH:D008985), amino acids (MESH:D000596), -acid (MESH:D000143), AE (-), nevirapine (MESH:D019829), dimethyl sulfoxide (MESH:D004121),  (MESH:D000949),  (MESH:D018984)
- **Species:** Qubevirus faecium (species) [taxon 39804], Macaca mulatta (rhesus macaque, species) [taxon 9544], Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus 1 (no rank) [taxon 11676]
- **Cell lines:** RM3 — Homo sapiens (Human), Ataxia telangiectasia syndrome, Transformed cell line (CVCL_XY12), AH-2 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_A8MQ), AH-3 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_B5H0)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC4547780/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4547780/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC4547780/full.md

---
Source: https://tomesphere.com/paper/PMC4547780